

29th June 2020

Mr Linus Power MP
Chair, Economics and Governance Committee
Maxima House, 1-3 Helen Street
HILLCREST QLD 4118

Via: logan@parliament.qld.gov.au egc@parliament.qld.gov.au

Dear Mr Power

Re: Submission to the Inquiry into the Queensland Government's Economic Response to COVID-19

Thank you for the opportunity to provide a submission to the Economics and Governance Committee on the *Inquiry into the Queensland Government's economic response to COVID-19*. The Pharmacy Guild of Australia, Queensland Branch has provided a detailed submission to the committee secretary.

I would like to extend an offer to present on behalf of Queensland community pharmacy at any public hearings on this matter as this inquiry progresses.

Should you have any questions regarding this submission, or to arrange attendance at a public hearing, please contact me at the Pharmacy Guild of Australia, Queensland Branch on 07 3831 3788 or

Yours sincerely

Professor Trent Twomey
Queensland Branch President

Cc: Ms Lucy Manderson, Committee Secretary

Email: guild.qld@qldguild.org.au Internet: www.guild.org.au



29th June 2020

Committee Secretary
Economics and Governance Committee
Parliament House
George Street
Brisbane QLD 4000

Via: egc@parliament.qld.gov.au

#### RE: Submission to the Inquiry into the Queensland Government's Economic Response to COVID-19

The Pharmacy Guild of Australia, Queensland Branch ("PGAQ") welcomes the opportunity to provide a submission to the *Economics and Governance Committee* on the *Inquiry into the Queensland Government's economic response to COVID-19.* 

PGAQ would like to acknowledge all Queenslanders and the impact that the COVID-19 pandemic has had across the State, and in particular to those who have tragically lost their lives or had their livelihoods affected.

PGAQ commends all levels of Governments, and government agencies for their overall response to the COVID-19 pandemic. The positive position we find ourselves in today, is in no doubt due to the governments' approach of listening to the medical experts and taking a proactive and rapid response to implementing measures to protect all Queenslanders.

PGAQ also adds particular thanks to the Treasurer and Minister for Infrastructure and Planning, Hon. Cameron Dick, for inviting PGAQ to contribute to the *Essential Goods Supply Committee* through the Department of State Development, Manufacturing, Infrastructure and Planning and provide advice regarding essential medicines supply issues affecting the State during the pandemic.

#### About the Pharmacy Guild of Australia

The Pharmacy Guild of Australia is the national peak organisation representing community pharmacies in Australia. It strives to promote and support community pharmacies as the appropriate providers of primary frontline healthcare through optimum therapeutic use of medicines, medicines management and other related services. Community pharmacies provide timely, convenient and affordable access to the quality and safe provision of medicines – most notably through the Pharmaceutical Benefits Scheme (PBS) – and other healthcare services by pharmacists who are highly skilled and qualified health professionals.

Community pharmacy is an essential and trusted part of Australia's primary healthcare system. Each year there are 458 million patient visits<sup>1</sup> (approximately 8.8 million per week) to community pharmacies making pharmacists the most visited healthcare professional in Australia. The community pharmacy network, which represents over 5,800 community pharmacies and a

<sup>&</sup>lt;sup>1</sup> PBS Date of Supply, Guild Digest, <a href="http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0">http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0</a>



workforce of approximately 80,000 pharmacists and pharmacy assistants, is one of Australia's most accessible health networks, dispersed right across urban, regional and remote areas.

In Queensland, there are over 1,200 community pharmacies across the state, delivering highly accessible professional health services, medicines and medication advice. PGAQ represent the owners of community pharmacies in Queensland and is committed to working with other healthcare professionals, stakeholders, community organisations, and Government in Queensland to improve safe and quality healthcare services and health infrastructure that aim to support all Queenslanders, including in times of crisis or disaster.

PGAQ commends the Queensland Government on the range of economic support activities aimed at supporting industry and employers throughout the COVID-19 pandemic. This submission will address some of the issues and barriers that community pharmacy experienced, with a number of recommendations for consideration to improve future activities during COVID-19, or indeed, if and when another emergency or disaster situation should arise.

#### The Exceptional Community Pharmacy Response to COVID-19

The community pharmacy network has been on the frontline of Queensland's response to the COVID-19 pandemic, ensuring continued access to medicines and primary health care services, as well as a source of education, advice and reassurance for all Queenslanders.

Community pharmacies have been faced with many pressures during this time. They have sustained increased workloads and the need to rapidly adapt systems and workflows to address issues stemming from panic buying of medicines, medicine shortages, telehealth image-based prescriptions, social distancing and physical restriction measures, heightened infection control procedures, sourcing personal protective equipment for staff and the public, and the high demand for influenza vaccinations. They have been on the end of verbal and physical abuse in trying to uphold restrictions and measures put in place by the Government regulations. They have been coming to work each day amongst fears for their own, and their families, health and safety.

To preface the impact of the pandemic directly on community pharmacy businesses, PGAQ is aware of two (2) positive cases of COVID-19 found in Queensland pharmacy assistants working on the front line during the lockdown period. PGAQ commend the Queensland Government and the Department of Health for providing these individuals and their employers clarity on the steps to follow after testing and after confirmation of a positive COVID-19 case. The community pharmacy sectors ability to implement the recommended hygiene and social distancing measures, as well as implementing adjustments to rosters (such as 'split teams' of pharmacy staff) ensured that the community pharmacy network remained open to provide primary healthcare and vital medication services to Queenslanders.



Community Pharmacy Delivered Substantial Cost-Savings to the Queensland Health System
Through COVID-19, Long-term Reform is Needed to Drive Greater Economic Benefit

#### **Recommendation 1**

The Queensland Government acknowledge the health system savings delivered through community pharmacy during the COVID-19 pandemic and move to implement lasting health system reform measures, enabling greater health system savings through community pharmacy for the benefit of all Queenslanders.

The COVID-19 pandemic represents both health and economic challenges to Queensland, community pharmacy sits at the cross-roads of both of these challenges, as accessible providers of primary healthcare and as a distributed network of small businesses serving communities across all reaches of the State.

Queensland Health implemented measures to support timely patient access to medicines through the time-limited Drug Therapy Protocol – Communicable Diseases Program<sup>2</sup>. Therapeutic Substitution, Continued Dispensing and Emergency Supply mechanisms enabled through the time-limited Communicable Diseases Program in community pharmacy undoubtedly resulted in productivity gains, reduced absenteeism and reduced unnecessary hospitalisations all without a single incidence of misadventure. PGAQ call on the Queensland government to improve, expand and extend these measures to become part of permanent Queensland legislation, to provide long-term economic and health benefits to Queenslanders.

#### **Preventable Hospital Presentations**

By staying open and remaining an accessible point of call for primary healthcare during the pandemic, the community pharmacy network reduced hospital presentations and reduced the potential for clustering of the virus at Queensland emergency departments by ensuring medication continuity for Queenslanders, through the Communicable Diseases Program measures adopted. PGAQ urge the Queensland government to strengthen and improve these measures so that they provide the intended benefits to patients and so that they are made into permanent measures through Queensland legislation.

For long-term health system reform, the community pharmacy network needs to be empowered to reduce unnecessary hospitalisations. PGAQ have developed a proposal for **an autonomous prescribing trial in North Queensland**, to demonstrate solutions that will benefit Queenslanders' access to primary healthcare and generate health system savings (see appendix I).

Prescribing assessment tools<sup>3,4</sup> are available and adaptable to upskill pharmacists, PGAQ call on the Queensland Government to enable pharmacists to practice to the full extent of their clinical scope.

<sup>&</sup>lt;sup>2</sup> Drug Therapy Protocol – Communicable Diseases Program <a href="https://www.health.qld.gov.au/">https://www.health.qld.gov.au/</a> data/assets/pdf file/0036/443988/dtp-comm-disease-program.pdf

<sup>&</sup>lt;sup>3</sup> Hardisty J, Davison K, Statham L, et al. Exploring the utility of the Prescribing Safely Assessment in Pharmacy Education in England: Experiences of pre-registration trainees and undergraduate (MPharm) pharmacy students. International Journal of Pharmacy Practice 2019, 27, pp.207-213. https://pubmed.ncbi.nlm.nih.gov/30088295/

<sup>&</sup>lt;sup>4</sup> Harrison C, Hilmer S. The Prescribing Skills Assessment: A step towards safer prescribing. Australian Prescriber, Vol 42: 5 2019. https://www.nps.org.au/assets/p148-Harrison-Hilmer-v2.pdf



#### Access to the National Immunisation Program (NIP) to Keep Queenslander's Healthy

Community pharmacy has seen an increased demand for the seasonal influenza vaccine this year due to community concern, Government advice and Home Telehealth by prescribers. Queensland pharmacists are also able to administer a number of other vaccines that are listed on the NIP, including Pneumococcal, Meningococcal and Pertussis vaccines. Many people who are eligible for NIP vaccines prefer to use their local community pharmacy because of convenience but must pay the full price for the vaccine and service. Appropriately trained pharmacists in Queensland should be given access to the NIP to best support the health of the community and ensure equitable and affordable patient access.

Allowing NIP access through community pharmacy will ensure all Queenslanders, especially those most vulnerable, will be able to access vaccination services across the state as we navigate through one of the most challenging influenza seasons in our nation's history. Community pharmacists are already able to deliver NIP vaccinations to their patients in Victoria, Western Australia and the ACT, the Queensland Government need to move to allow Queenslanders this same level of community access.

The COVID-19 pandemic also highlighted the urgent need to increase the breadth of vaccination services that Queenslanders of all ages can access through the established vaccination network of community pharmacies, while general practices closed their doors, community pharmacy stayed open to continue providing vaccines. There are significant economic benefits and health system savings to be gained by ensuring all Queenslanders eligible for NIP vaccines can conveniently access them through their local pharmacy, reducing the risk of unnecessary hospitalisations from vaccine-preventable illness.

The Seventh Community Pharmacy Agreement, signed on 12 June 2020, has included a commitment by the Commonwealth to harmonise vaccination administration by pharmacists across all jurisdictions, including access to the NIP. PGAQ urge the Queensland Government to move quickly in rectifying the inequity of access that Queenslanders experience with regard to the NIP, so that that Queenslander's reap the health and economic benefits associated with timely vaccinations.

#### **Medicine Shortages Cost the Economy**

Medicines shortages are an ongoing problem for Queenslanders and a significant administrative burden for community pharmacies and prescribers. Therapeutic substitution by a pharmacist without the need to consult a prescriber is permitted in equivalent countries (e.g. USA and Canada)<sup>5</sup> without compromising safety and should be developed further in Queensland to manage medicines shortages.

A medicine shortage is not only frustrating and inconvenient for patients and their carers, but it can potentially worsen a person's health condition by interrupting treatment and affecting medicine adherence and persistence. Such interruptions can affect the control of a person's condition and has been associated with increased mortality, adverse medicine events, errors, increased hospitalisation

<sup>&</sup>lt;sup>5</sup> https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.12.1260



as well as detrimental effects on a person's quality of life. The impact of COVID-19 on the global medicine supply chain and the anxiety-induced stockpiling of medications by concerned patients has amplified this already serious medication shortage issue. These global supply chain issues are not going to resolve in the near-term, future medicine shortages are going to remain a permanent feature of the healthcare system. Appendix II provides further information about therapeutic substitution to ensure ongoing continuity of therapeutic care for Queenslanders affected by medicine shortages.

PGAQ urge the Queensland Government to move as the first state to implement sensible, permanent measures to enable therapeutic substitution and continued dispensing arrangements for pharmacists to ensure Queenslanders receive effective continued care for the chronic conditions beyond the pandemic.

#### Travel Health Measures Through Community Pharmacy as Borders Re-Open


As the Queensland Government continue to support the economy through the pandemic recovery, the time will come to return to the free movement of people across our domestic and international borders to ensure our economy recovers as soon as possible. As 'travel-bubbles' begin to emerge between Queensland, New Zealand, Southeast Asia and beyond, travel health measures need to be put in place to keep travellers safe on their journey and keep Queensland safe upon their return. Following the recommendations from the 2018 Queensland Government Response to the Health, Communities, Disability Services and Domestic and Family Violence Prevention Committee's Report No. 12 – Inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Queensland<sup>8</sup>, PGAQ have developed a Proposal to extend the range of Travel Medicine services available through community pharmacies in Queensland (see appendix III), outlining how all Queensland community pharmacies can provide comprehensive travel health services.

PGAQ call on the Queensland Government to implement the travel medicine recommendation of the 2018 Queensland Parliamentary Inquiry so that Queenslanders can, without financial cost to the State, receive all the necessary medications and travel health advice to support safe travel from their local community pharmacy. This measure represents an important step in balancing the health and safety aspects of a return to open borders and supporting Queensland's economy through this appropriate enablement of the highly skilled community pharmacist workforce across Queensland community pharmacy businesses.

<sup>&</sup>lt;sup>6</sup> The impacts of medication shortages on patient outcomes: A scoping Review; 2019; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499468/

https://www.abc.net.au/news/2020-03-24/coronavirus-panic-buying-sees-shortage-of-vital-medicine/12081436

<sup>&</sup>lt;sup>8</sup> Health, Communities, Disability Services and Domestic and Family Violence Prevention Committee's Report No. 12 – Inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Queensland. https://www.parliament.qld.gov.au/documents/tableOffice/TabledPapers/2018/5618T1639.pdf



#### **Commercial Leasing**

#### **Recommendation 2**

That the good faith leasing principles be extended to the recovery period to ensure tenants have certainty over leasing arrangements and costs.

The Federal Government's Mandatory Code of Conduct on commercial leasing recognised the significant burden faced by both landlords and tenants in maintaining a presence to continue operating in the circumstances, providing employment opportunities and, services to the community.

The Code's set of good faith leasing principles apply to negotiating amendments in good faith and these principles need to be extended to the recovery period to ensure tenants have certainty over leasing arrangements and costs.

Any agreed amendments to leasing arrangements, taking into account the impact of the pandemic on the tenant, with specific regard to its revenue, expenses and profitability becomes impossible if only 'turnover' or JobKeeper are used as the eligibility benchmark to receive financial assistance for a wage offset or rental waiver. It is impossible for pharmacy owners to negotiate a rental deferment unless there is a 30% drop in turnover. Instead, downturn in profit should be used as the indicator of ability to pay recognising the size and financial structure of these businesses.

Eligibility for JobKeeper can currently be met at any time for the period to 27 September 2020, whereas COVID-19 related lease negotiations are occurring now. It must be noted that even if a small business is not eligible for JobKeeper currently, it does not mean that they are not suffering a negative trading impact from COVID-19, and therefore it should not exclude them from access to the Code, as it currently does.

It is also inequitable; a business that is now experiencing a reduction in turnover of 15-25 per cent will not receive coverage (nor the benefits of JobKeeper to assist supporting staff payments). It is an unintended consequence that SMEs with reductions in turnover of less than 30 percent are therefore ineligible for JobKeeper support. These businesses would be in a significantly more dire situation (in terms of meeting its fixed costs) than a business whose turnover did in fact drop 30 per cent was receiving full JobKeeper support.

Turnover is an inappropriate indicator as it often does not reliably correlate with the financial ability of the business to afford expenses (such as rent). In recent years, community pharmacies have been operating on declining profit margins due to competitive pressure, high fixed costs (such as rent) and subdued economic conditions. A small reduction in turnover, with an inflexible fixed cost base, may be sufficient to put the small business owner into an operating loss scenario.

Importantly for community pharmacy, profitability also allows for consideration of the impact of the supply of high-cost medicines (however with a low return on investment) which can substantially and artificially increase pharmacy turnover.

It is critically important that a small business tenant needs to be able to get advice and help to increase their understanding of market and rental trends and movements. Some leases and associated rental abatement or incentive agreements contain confidentiality clauses that prohibit a



tenant from disclosing the information. The use of confidentiality clauses is becoming increasingly common with tenants that do not have this restriction on them being directed to sign one and surrender detailed financials before negotiation can begin. This leads to opaque and distorted markets that disadvantage small business due the lack of transparency. Multi premises landlords, e.g. shopping centres, syndicates and property agents, have access to substantially more market information that a small business tenant. Again, without access to the national code, small businesses are exposed to this behaviour.

Therefore, it is concerning that the intent and principles of the National Code will not be honoured due to the focus on (1) JobKeeper eligibility and/or (2) a requirement for a decrease in turnover (and not profitability) and as a result many small business will not only suffer financial stress or hardship as a result of COVID-19 but will not be able to access rental support.

It was the responsibility of the respective State and Territory Governments to be fully on board for the implementation of the Code by developing complementary legislation to protect businesses (up to \$50 million turnover) in their jurisdictions. There have been issues/concerns with the implementation process and development of legislation/regulations to support the Leasing Code, specifically that it has varied significantly across states and territories, and outside the intent of National Cabinet.

PGAQ recommend that the Queensland Government adopt the implementation of the Code and develop appropriate legislative instruments to protect Queensland community pharmacy businesses.

#### In Conclusion

Thank You to the Queensland Government for the economic response to COVID-19 to date and the ongoing support measures for Queensland workers and industry, including the community pharmacy sector.

The COVID-19 pandemic is causing significant disruption and strain to the lives of all Queenslanders, with potentially long-term health, social and economic consequences.

Ensuring there is a primary health system fit for purpose during a time of disaster, crisis or emergency is what Queenslander's expect and deserve.

Recognising the critical frontline primary healthcare role Queensland pharmacists play during disasters and emergencies and utilising their training to its full extent, including in recovery, relief and future planning efforts, will ensure that all Queensland communities have the best access to the essential health services they need. This includes a network of community pharmacies across Queensland that can be called on to contribute to a national coronavirus vaccination program, if/when a vaccine is developed.

The economic benefits that the community pharmacy network provides through ensuring Queenslanders have accessible primary healthcare services and through reducing unnecessary hospitalisations are substantial, PGAQ urges the Queensland Government to work collaboratively in long-term health reform measures to enable community pharmacists to do more for Queenslanders and generate even greater savings for Queensland's health system.



I, as the Branch President of the Pharmacy Guild of Australia Queensland, would like to extend an offer to present on behalf of Queensland community pharmacy at any public hearings on this matter as this inquiry progresses. Should you have any questions regarding this submission, or to arrange attendance at a public hearing, please contact the Pharmacy Guild of Australia, Queensland Branch Director Gerard Benedet on 07 3831 3788.

Kind regards

Professor Trent Twomey
Queensland Branch President

Pharmacy Guild of Australia, Queensland Branch

#### Appendix I

Pharmacy Guild of Australia, Queensland Branch North Queensland Proposal: Solutions to Reduce Unnecessary Hospitalisations

#### Appendix II

Summary of Therapeutic Substitution by Pharmacist

#### **Appendix III**

Proposal to Extend the Range of Travel Medicine Services Available Through Community Pharmacies in Queensland





The Pharmacy Guild of Australia, Queensland Branch affirms that Aboriginal People and Torres Strait Islander People are the Indigenous People of Australia.

We acknowledge and pay respect to the past, present and future Traditional Custodians and Elders of this nation.

We also recognise those whose ongoing effort to protect and promote Aboriginal and Torres Strait Islander cultures will leave a lasting legacy for future Elders and leaders.



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions



## **Background**

- Approximately 170 pharmacies in the NQ catchment area.
- 12 QLD towns PhARIA rated 'moderately accessible' to 'remote' include a pharmacy but no medical centre; and 39 include a pharmacy and only one medical centre.<sup>1</sup>







## **Background**

- In regional areas, 65% of people live within 2.5km of a pharmacy.<sup>1</sup>
- Approximately 70 million individual patient visits annually in QLD, including afterhours and weekends.
- Pharmacists are one of the most trusted professions recent public opinion surveys have shown that 84% of adults trust the advice they receive from pharmacists.<sup>2</sup>



## **Background**

- Pharmacists complete minimum 5 years training as well as ongoing, mandatory professional development.
- Pharmacists are medicines experts with broad training in disease prevention, management and treatment with a focus on patient outcomes.
- Pharmacists operate within extensive professional, ethical quality and risk management frameworks.
- Governing boards define registration standards, codes, guidelines, policies and scope of practice to which a pharmacist is qualified to operate.



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions





"Right now, our system is dangerously imbalanced towards expensive tertiary hospital care and away from community-based, preventive and primary healthcare," Dr Miles said.

"Many parts of Queensland no longer have a GP. Even in large centres like Mackay and Gladstone, there are no bulk-billing GPs left.

"Many clinics are booked days or weeks in advance. But it's even worse in smaller towns like Mission Beach, a two-hour drive from Cairns, where their only GP clinic shut its doors for good before Christmas.

"For more and more people, emergency departments are the only healthcare option available when they need it. But as fantastic as our EDs are in emergencies, they aren't the best place to delivery primary care."

- The Australian Newspaper 8/01/2020



We know that demand for hospital emergency departments and GP services is outstripping supply and the problem will only get worse over coming years;

- Approximately 1.4 million Queenslanders living with chronic illness.
- Over 179,000 potentially preventable hospitalisations in Queensland.<sup>1</sup>
- Demand for GP services is forecast to outpace supply, resulting in a shortfall from 2020 onwards.<sup>2</sup>
- 1.3 million Australian's did not visit a GP or specialist because the cost was too high.<sup>3</sup>



AIHW (Australian Institute of Health and Welfare) 2019. Potentially preventable hospitalisations in Australia by age groups and small geographic areas, 2017–18. Cat. No. HPF 36. Canberra: AIHW

<sup>2.</sup> Deloitte General Practitioner Workforce Report 2019

<sup>3.</sup> Australian Institute of Health and Welfare (AIHW), Patients' out-of-pocket spending on Medicare services, 2016–17, p. 15, available here

### Case Study: Out of Hours Emergency Supply

Gary, a 55 year-old male living in Brisbane's inner suburbs has run out of his packet of Candesartan, used to treat his hypertension and high blood pressure. Gary has one more repeat on his prescription, however the original is over 12 months old and has expired.

Gary goes into his closest community pharmacy on a Sunday afternoon, unaware the prescription has expired and finds the pharmacist is not allowed to supply the medication. The pharmacist checks Gary's My Health Record notes that he has been on the medication for a number of years, the dose has been stable, and he has been counselled by pharmacists in the past on the use of this medication. The pharmacist currently only has the option to dispense an emergency supply for three days, however they have been advised by the pharmacy owner not to do as this will require them to break open a whole packet of medications, restricting the future sale of the remainder of the packet.

As it is a Sunday, there are no GP clinics open. Even if Gary had three days' supply it is unlikely he would be able to get an appointment with his GP within the next three days, unless it was an emergency. Gary's only option is to go to the emergency department at the public hospital to get a script, where the doctor he sees has a limited view of his medical history and the medicine he is currently taking.





# Queensland Goverment to fund extra beds to cater for flu season

THE Palaszczuk Government will fund up to 90 extra beds across Queensland's southeast to keep up with increased demand during the winter flu season.

#### Plan to let kids get flu jabs in chemists

TORY SHEPHERD STATE EDITOR

CHILDREN as young as 10 would be able to get the flu jab at pharmacies, under changes the State Government is planning in the wake of a horror influenza season.

Currently children have to be at least 16 to skip the doctor and go to a chemist. Health Minister Stephen Wade said lowering that age would in-



crease the proportion of vaccinated children. Flu has killed 106 South Australians this year.

"very dangerous" and getting more children vaccinated would build up herd immunity in SA. "We have just experienced a particularly bad flu season and it is important we are proactive in preventing the disease by ensuring as many people are vaccinated as possible." he said.

SA's chief public health officer Nicola Spurrier said it would boost the number of immunised children because it would be easier for families to fit the jab into their busy lives.





### Comparing pharmacists scope of practice

		CANADA <sup>1</sup>	UK <sup>2</sup>	QLD
Prescription authority for common ailments	Independently	<b>√</b>	✓ 3	*
	Changing dosage	✓	✓	×
	Renew and extending prescriptions	<b>√</b>	✓	*
	In an emergency	✓	✓	✓
Immunisations and injections	Influenza	✓	✓	✓
	Travel vaccines	✓	✓	×
Treatment for minor ailments		✓	✓	×



- 1. Using the pharmacists scope of practice model of Alberta Canada
- 2. Includes Schedule 2 to 5, except diamorphine, dipipanone or cocaine for treatment of addiction
- 3. Pharmacists in the UK are required to undergo extra prescribing accreditation and training but are able to prescribe any medicines for guild\_org\_au any medical condition within their competence



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions



## How community pharmacy can help

An estimated \$248m p.a. saving to the QLD Government, including;

- Approximately \$63m p.a saving to QLD Government if community pharmacists could administer more vaccinations.<sup>1</sup>
- Approximately \$176m p.a. saving to QLD Government if community pharmacists could treat more minor ailments.\*1
- Approximately \$9m p.a. saving to QLD Government if community pharmacists could dispense more medicines under continued dispensing.



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions





#### **Injections**

- **Immunizations**
- Travel medicine
- Other injectable medications



#### **Prescribing**

- Refill authorization
- Adaptation
- Independent prescribing
- Deprescribing



#### **Laboratory Tests**

- Lab tests
- Point of care testing
- diagnostic testing (e.g., pulmonary function testing)



#### **Disease Management**



- Screening
- Prevention



- Chronic diseases
- Acute (common ambulatory) conditions





### **Trial overview**

- Tropical Australian Academic Health Centre (TAAHC) area conducts a three year trial in partnership with Community Pharmacists (The Guild) to reduce unnecessary hospitalisations and reduce GP demands.
- The trial is supported by JCU Pharmacy School to map and verify the savings and the change in patient behaviour throughout the trial.
- This innovative trial would lead Australia's primary health care agenda and work to promote better patient outcomes from Mackay to Cape York.



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions





### **Trial components**

#### The main areas of the trial would be;

- Vaccinations
  - Expand range to include all travel and health vaccinations (excluding Yellow Fever)
  - Include access to NIP for all vaccinations
  - Lower vaccination age to 10
- Minor ailments
  - Delivery of services including basic wound care, non-complex ENT infections, pain management (i.e. migraine)
  - Medication adherence including blood pressure cholesterol management, COPD and asthma control
  - UTI trial overlap
- Continued dispensing
  - Lift emergency supply maximum quantity from 3 days to match the quantity allowed for in the PBS
  - Expand the list of medications a pharmacist can dispense under continued dispensing



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions



### **Evaluation & monitoring**

A robust evaluation and monitoring system would include;

- Research partners from TAAHC would be brought on board to monitor and assess the trial.
- Data collection would be conducted by the Trial Working Group or partnerships.
- Survey data (qualitative and quantitative) behavioural change is vital to reduce unnecessary hospitalisations.
- Savings to be reported on an annual basis.



- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions





### Driving behavioural change

To ensure the trial is robust and delivers less unnecessary hospitalisations, a key component will be to drive behavioural change.

- Consumer awareness and promotion campaign via North Queensland HHS's to encourage behavioural change.
- Grassroots engagement / local champions to encourage behavioural change.
- Consumer and provider data collection regarding uptake and roadblocks.



# Agenda

- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions



# **Next steps**

- Present to TAAHC decision makers.
- Approval of trial concept and additional work.
- TAAHC and Guild lobby Government for trial.
- Government to support trial.
- Government change to regulations to support the trial.
- TAAHC and Guild working group/ taskforce.
- Training and rollout completed by the Guild and trial partners.



# Agenda

- 1. Background
- 2. Change is needed
- 3. How community pharmacy can help
- 4. Trial overview
- 5. Trial components

- 6. Evaluation & monitoring
- 7. Driving behavioural change
- 8. Next steps
- 9. Summary
- 10. Questions



# Summary

- No cost to Government
- Approximately 170 pharmacies in the Northern Queensland catchment area.
- In regional areas, 65% of people live within 2.5km of a pharmacy.1
- Over 179,000 potentially preventable hospitalisations in Queensland.<sup>2</sup>
- Demand for GP services is forecast to outpace supply, resulting in a shortfall from 2020 onwards.<sup>3</sup>
- 1.3 million Australian's did not visit a GP or specialist because the cost was too high.4
- An estimated \$248m p.a. saving to the QLD Government.<sup>5</sup>



<sup>1.</sup> Guild Submission to the Review of Pharmacy Remuneration and Regulation 2016

<sup>2.</sup> AIHW (Australian Institute of Health and Welfare) 2019. Potentially preventable hospitalisations in Australia by age groups and small geographic areas, 2017-18 . Cat. No. HPF 36. Canberra: AIHW

Deloitte General Practitioner Workforce Report 2019

Australian Institute of Health and Welfare (AIHW), Patients' out-of-pocket spending on Medicare services, 2016–17, p. 15, available here

Services of practice opportunity assessment August 2018

<sup>5.</sup> EY Scope of practice opportunity assessment, August 2018

# Summary — precedent in other OECD Submission 011 countries

		CANADA 1	UK <sup>2</sup>	QLD
Prescription authority for common ailments	Independently	✓	√ 3	*
	Changing dosage	✓	✓	×
	Renew and extending prescriptions	✓	✓	*
	In an emergency	✓	✓	✓
Immunisations and injections	Influenza	✓	✓	✓
The control of the co	Travel vaccines	✓	✓	×
Treatment for minor ailments		✓	✓	×



- 1. Using the pharmacists scope of practice model of Alberta Canada
- Includes Schedule 2 to 5, except diamorphine, dipipanone or cocaine for treatment of addiction
- Pharmacists in the UK are required to undergo extra prescribing accreditation and training but are able to prescribe any medicines for any medical condition within their competence



# Questions?


### **Trent Twomey**

Pharmacy Guild of Australia, Queensland President Senior National Vice President Adjunct Professor, JCU School of Medicine & Dentistry Trent.Twomey@qldguild.org.au | 0412 716 699

### **Gerard Benedet**

Pharmacy Guild of Australia, Queensland Branch Director Gerard.Benedet@qldguild.org.au | 0408 762 216





### **Summary of Therapeutic Substitution by Pharmacist**


### **Outcome Sought**

- 1. Therapeutic substitution by pharmacists as a mitigation strategy to more effectively and efficiently manage medicines shortages, and thereby ensure continuity of appropriate clinical care for Australian patients.
- 2. Implementation of regulatory amendments in State and Territory legislation to enable therapeutic substitution by pharmacists according to contemporary therapeutic guidelines in order to ensure continuity of treatment and care, particularly for at-risk patients.
- 3. Implementation of regulatory amendments in Commonwealth legislation so that therapeutic substitution by a pharmacist can be claimed as a pharmaceutical benefit where appropriate.

### **Key Points**

- Medicine shortages are an ongoing problem for the Australian community and a significant administrative burden for pharmacists and staff of community pharmacies as well as prescribers and practice staff
- Medicine shortages risk disrupting a person's medicine treatment with associated health consequences
- There has been precedence in Australian jurisdictions to help at-risk patients NT arrangements in 2016-17 for the extended shortage of Metformin XR<sup>1</sup>
- For a person presenting with a prescription for the unavailable medicine, the pharmacist
  assesses the patient according to contemporary therapeutic evidence and uses their
  professional judgement to determine whether medicine substitution is appropriate. If
  substitution is appropriate:
  - Consumer consent for substitution is obtained and appropriate counselling is provided.
  - The prescription is annotated and the pharmacist dispenses a suitable alternative, including as a pharmaceutical benefit, if eligible.
  - The pharmacist makes a record of the assessment and uploads details of the substitution to the patient's My Health Record.
  - The pharmacist continues to monitor and review the patient while using the substituted therapy, referring the patient to their prescriber for any identified issues that cannot be resolved.
- Provides an efficient and effective mitigation strategy for the increasing incidences of medicines shortages, including during emergencies or pandemics

<sup>&</sup>lt;sup>1</sup> NT Department of Health Best Practice Communique 16-04 Primary Health Care Pharmacy Group – Metformin XR Shortage **Queensland Branch** 



### **Patient Benefits**

- Continuity of care and treatment when there is a medicine shortage
- Reducing risk of non-adherence and associated poor health outcomes
- Less likely to experience stress and anxiety over possibility of interruption to treatment
- Greater patient convenience
  - Ensuring access to equivalent treatments
  - Subsidised (PBS) pricing when supported by the Commonwealth
  - Particularly when presenting to a community pharmacy after-hours, or on weekends or public holidays

### **Community Benefits**

- Changes to GP and ED workloads
  - o greater capacity for GPs and EDs to manage more complex health conditions
  - o improved availability and reduction in wait times at GPs and EDs
  - reduced presentations to GPs and EDs for the purpose of prescription reviews and associated administrative tasks to manage a medicines shortage
- Improved long-term and disaster/pandemic management enables ongoing treatment for patients when the supply of their prescribed medicine is disrupted

### **Prescribers**

- Promotes collaborative working arrangements between prescribers and pharmacists
- Fundamental role and responsibility of prescribers for diagnosis, initial prescribing and timing for review remain unchanged
- Reduced volumes and administrative burden of managing medicines shortages
- Confidence in continuity of therapy for their patients


### **Community Pharmacy**

- Improved workload with less workflow interruptions for pharmacists to provide clinical care
- Community pharmacies not exposed legally, professionally or financially in order to ensure continuity of care for patients
- Reduced volumes and administrative burden of managing medicines shortages
- Greater efficiency for managing medicines shortages, particularly for people presenting after hours, on weekends or public holidays

### **Governments**

- Improved disaster/pandemic management enables ongoing treatment for patients when the supply of their prescribed medicine is disrupted
- Risk management strategy for increasing incidence of medicines shortages to facilitate ongoing treatment and care
- Reallocation of critical health resources from reduction in GP and ED presentations from interruption to a person's medicines due to shortages

#### **Queensland Branch**



- Savings from a reduction in patient morbidity and health service use due to poor adherence as a result of medicines shortages
- Improved efficiency in the health system

# Proposal to extend the range of Travel Medicine services available through community pharmacies in Queensland

October 2019

### **Associate Professor Ian Heslop**

Pharmacy, College of Medicine and Dentistry,

James Cook University

Townsville, Queensland

### The Pharmacy Guild of Australia

Queensland Branch

132 Leichhardt Street Spring Hill QLD 4000

PO Box 457, Spring Hill QLD 4004

**PH** +61 7 3831 3788 **FAX** +61 7 3832 0871

http://www.guild.org.au

### Contents

1.	Introduction	3
2.	Background	3
3.	Requirements of a comprehensive travel health service	5
3	.1 Can these requirements be provided from a community pharmacy in Queer what is required?	
	3.1.1 A formal and thorough, pre-travel risk assessment	6
	3.1.2. An individualised risk management strategy for each traveller	6
	3.1.3. Risk communication providing reliable, current and evidence-based,	written and
	verbal, information	8
	3.1.4. A formal and thorough assessment system for returning travellers to	identify travel-
	related health problems and ensure the appropriate treatment of any	health
	problems	8
	3.1.5. The care and advice given to the traveller is documented and record	8be
4	. Summary	8
5	. References	9
6	. Appendices	11
	Appendix I: Suggested Schedule 4 Prescription Only Medicines and Vaccin routine pre-travel consultations	•

### 1. Introduction

Every year, many Australians travel overseas for work, leisure and/or to visit friends and relatives. Yet many do not obtain pre-travel health advice prior to their journey, thereby exposing themselves and the wider Australian population to travel-related health risks. In many countries, pharmacists play an important role in the provision of travel health services, often providing comprehensive care to travellers who do not seek travel health advice and services from other health providers. However, in Australia, current legislation limits the level of service that pharmacists are able to offer. This short paper briefly discusses the roles and impact of pharmacists in the area of travel health, the requirements of a comprehensive travel health service and current limits on practice in Australia. In the process, some recommendations are made that, if implemented, would allow pharmacists to make a greater contribution in the area of travel health.

### 2. Background

In 2017, the United Nations World Tourism Organization (UNWTO) UNWTO reported 1,323 million international tourist arrivals and that year-on-year growth in international tourist arrivals continued for an unprecedented eighth consecutive year. Travellers are increasingly visiting higher risk destinations in Africa, Asia and other developing countries, often at short notice and with little or no planning. In addition, reports suggest that travellers take greater risks when overseas, that their perceptions of risk are decreasing and that many travel without insurance. 1-3

It has been noted that travellers are at greater risk of morbidity and mortality while travelling than when they are at home, with between 65-75% of visitors to developing countries experiencing at least one health problem when overseas.<sup>4-6</sup> However, although most health problems experienced by travellers are classified as minor, non-life-threatening and/or preventable, such as traveller's diarrhoea, international travellers still face significant infective and non-infective health risks that can have major implications to the traveller while overseas and to the Australian public and health system on their return. <sup>5, 7-10</sup>

Modern travellers have ready access to pre-travel health advice from an ever increasing range of information sources. <sup>11</sup> The growth of the internet means that travellers can increasingly and easily access information themselves, although the quality of the information they find may vary. The development of travel medicine as an independent specialty has resulted in the increased availability of specialist travel clinics in metropolitan centres and general practitioners (GPs) still play a major role in the provision of travel health services in many areas. <sup>11,12</sup> However, despite readily accessible information, studies repeatedly show that only 36-52% of international travellers obtain travel health advice before their journey meaning that a significant number of travellers remain at risk of travel-related health problems. <sup>13-18</sup>

Many international travellers already visit a pharmacy sometime during their preparations for their journey, either to collect medicines and/or vaccines prescribed by their doctor, to buy non-prescription medicines and first aid items or to check with a pharmacist whether it is necessary or worthwhile for them to visit a doctor or travel clinic prior to their journey.<sup>19-21</sup> In doing so, travellers are taking advantage of the pharmacy's location, convenience, extended opening hours and the ready availability of trained staff and, in countries like Australia, many pharmacists provide this advice and information free and on an *ad hoc* basis.<sup>20-22</sup> In doing so, community pharmacy-run travel health services present an attractive option for travellers who are

perhaps reluctant, time-poor or unable to visit a travel clinic or their GP for advice and/or when other sources of information are not readily available in their locality. 11,19,20,23,24

However, since the mid-1990s in a number of countries, notably the USA, UK and Canada, pharmacists have become increasingly involved in the provision of more formal travel health services. The exact services vary between regions and countries and are often dependent on local legislation. However, the services can be divided into three main categories. Firstly, referral information services that respond to questions from travellers about their need for vaccinations, antimalarials and other materials. The service provides the traveller with standard information resources and refers the traveller to an appropriate prescriber if vaccines and/or other medications are required.<sup>24-26</sup> Secondly, pharmacy-run immunisation services. These services were first developed in the USA and the UK, and were initially extensions of successful influenzavaccination schemes operating from community pharmacies.<sup>21,27,28</sup> Finally, in some countries, pharmacies offer full-service, comprehensive pharmacist-run travel clinics (PTCs) and a number of models exist in different settings.<sup>25-27, 29-31</sup> Examples include a pharmacist-run telepharmacy service operated by a large health insurer in a managed-care setting<sup>25, 26</sup> and a PTC in a primary healthcare setting within a university health centre.32 Both of these models operate in the USA and are fully operated by pharmacists and evaluations show that travellers are very satisfied with the services provided. In addition, it has also been shown that users of these services are less likely to be prescribed antimicrobials, antimalarials or vaccines that are divergent from standard guidelines.<sup>25,26,32</sup>

A number of examples also exist of successful PTCs operating from community pharmacies. <sup>21,27,28</sup> For example, Hind *et al* describe the evaluation of a pilot service in the Grampian region of Scotland. <sup>27</sup> This service was delivered from multiple pharmacies and was developed from a highly successful pharmacyrun influenza immunisation scheme. <sup>27,28</sup> A needs assessment study of the general public in the region found that 75% of respondents agreed/strongly agreed that pharmacies are convenient locations for travel health services and that 70% agreed that community pharmacies could successfully provide a 'one-stop shop' for travel health services. <sup>21,27</sup> Pharmacists completed a travel health and immunisation training program and then offered the service from their pharmacies. <sup>27</sup> In the service evaluation, it was found that 80% of the travellers questioned thought that the service provided value for money and that 98% would happily use the service again. <sup>27</sup> Other examples of successful PTC service models operating from community pharmacies also exist. <sup>30,33,34</sup>

A survey of Australian pharmacists' perceptions and practices in travel health has been performed.<sup>22</sup> It was found that two-thirds of respondents already provided some form of travel health service in their current practice.<sup>22</sup> However, most only provided information services, responding to simple travel-related health enquiries instigated by travellers and in most situations the workload was low. Few respondents performed full pre-travel risk assessments.<sup>22</sup> That said, 90% of respondents felt that travel health was an appropriate role for pharmacists even though at the time of the survey pharmacists were unable to offer immunisation services, antimalarials and antimicrobials without prescription.<sup>22</sup>

A PTC operating from a community pharmacy has been piloted and evaluated in North Queensland. The service offered travellers full pre-travel risk assessments, pre-travel counselling and education and included a referral pathway for travellers requiring vaccinations and/or medications that were unavailable from

I.M.Heslop October 2019 4

pharmacies without prescription. A particular niche area was identified for the service; to supply travel health advice to travellers visiting relatively low-risk destinations or travellers who may not normally obtain pretravel health advice from other sources, and it was found that the majority of clients during the pilot met this profile. The other remit of the service was to operate within then current legal and professional restrictions and again this requirement was met with 40.7% of the PTC's clients being referred to their GP after their pre-travel risk assessment, mainly for vaccinations or for the prescription of medications not available from pharmacies in Australia without an appropriate prescription. A training program for pharmacy staff, preand post-travel risk assessment and data collection tools and pharmacy-specific information resources for travellers were also developed and evaluated. Although traveller numbers in the trial were small, data (currently unpublished) suggests that travellers accepted and valued the service. The clients rated the PTC highly for both quality and usefulness and considered the PTC to be comparable to other travel health services. They were also very supportive of the role of the pharmacist in the area of travel health. As the pharmacy had private consultation rooms, neither the clients nor the pharmacists involved in the pilot project appeared concerned about any lack of privacy or confidentiality, a concern that is often raised by other health professions. Due to their accessibility, the pharmacists working within the PTC felt that travel health was an appropriate role for pharmacy and overall, they were happy with the pilot model and the resources used in the pilot. They also felt that they were adequately trained and were confident to perform the roles required. However, they did recognise that the model used in the pilot project was not currently financially viable. That said, potential efficiencies and changes were identified, such as the ability to supply travel vaccines, antimalarials and a small range of antimicrobials and other medicines without prescription and the conversion of paper-based traveller assessment tools to an electronic format would make the PTC more viable and also improve service delivery.

In summary, pharmacies are ideal sites from which travel health services can operate, as they are accessible, have a well-trained and skilled workforce, and often have extended opening hours. <sup>20,23,24,27</sup> Community pharmacy-run travel health services may be attractive to some travellers, including potentially those travellers who may not normally obtain pre-travel health advice from other sources. A greater availability of these services may, in turn, assist in decreasing the number of Australian travellers not obtaining pre-travel health advice before their journey thereby reducing the implications and consequences of the health risks faced by Australians overseas and on their return to Australia. <sup>20 23,24,27</sup> Finally, extending the range of vaccines that may be available from pharmacies and allowing a limited range of antimalarials, antimicrobials and other medicines to be available from pharmacies for travel-specific indications would improve the viability and convenience of community pharmacy-run travel services and the quality of the care offered to their clients.

### 3. Requirements of a comprehensive travel health service

The main aims of a travel health service are to prevent and/or minimise the health or other risks associated with travel for each individual traveller, and to manage any problems that may occur during their journey.<sup>35</sup> Therefore, the use of a risk management approach in the assessment of travellers is considered to be an integral and essential component of both pre and post-travel health services.<sup>3,4, 35-39</sup> The key elements of a high quality, comprehensive travel health service have been identified as:<sup>3,4 35-39</sup>

I.M.Heslop October 2019 5

- 1. A formal and thorough, pre-travel health risk assessment analysing the itinerary and full medical history, to identify both general and specific travel-related health risks for each individual traveller.
- 2. An individualised, risk management strategy for each traveller using, if appropriate, a combination of vaccines, medicine, education and guidance to prevent and/or reduce the risk of travel-related health issues at their planned destination(s).
- 3. A process of risk communication providing reliable, current and evidence-based, written and verbal, information which is understandable by the traveller in an appropriate manner.
- 4. A formal and thorough assessment system for returning travellers to identify travel-related health problems and ensure the appropriate treatment of any health problems.
- 5. The care and advice given to the traveller is documented, recorded and subsequently uploaded to My Health Record and shared with the traveller's nominated GP. In addition, records are to be maintained and stored for an appropriate length of time. 3,4,35-39

## 3.1 Can these requirements be provided from a community pharmacy in Queensland and/or what is required?

As discussed in section 2, the evaluation of overseas models<sup>21,23,27-34</sup> and the findings of the North Queensland (NQ) PTC pilot (currently unpublished) demonstrate that all of the key elements of a high quality, comprehensive travel health service can be successfully provided from community pharmacies and, in particular, in Queensland. However, the findings (unpublished) of the NQ PTC pilot also demonstrated that the model could be further modified so that an efficient, fully comprehensive travel health service delivering high quality care for the traveller can be delivered from all community pharmacies in Queensland. Specifically, the following modifications are recommended to ensure that each of the 5 key elements of a comprehensive travel service can be met:

### 3.1.1. A formal and thorough, pre-travel risk assessment

The pre-travel consultation is the fundamental component of the clinical, decision-making process in travel health and, as part of the NQ PTC pilot, a comprehensive literature review was performed to identify all of the key components of a pre-travel risk assessment and to develop a systematic and standardised questionnaire and interview tool to aid the interview and assessment process. Paper-based questionnaires were used in the pilot, however, these could be easily adapted for electronic use with an IT platform, thereby making the interview process more efficient and also aid in the maintenance of records.

### 3.1.2. An individualised risk management strategy for each traveller

A fully comprehensive travel health service should be able to provide each traveller with an individualised management strategy that will use, if appropriate, a combination of vaccines, medications, education and guidance to prevent and/or reduce the risk of travel-related health issues at their planned destination(s). At the time of the NQ PTC pilot, although pharmacists could assess, counsel and educate the traveller and supply items available over-the-counter in pharmacies (and did so successfully), they were unable to administer vaccines and could not supply prescription medications. As a result, many travellers (40.7%) needed to be referred to their GP for these services.

The range of medications required to meet the requirements of most international travellers is relatively small and can be divided into three main areas; Antibiotics and antimalarials, vaccines and other medicines. Appendix I lists a number of suggested Schedule 4 medicines and vaccines that would meet the needs of the majority of routine pre-travel consultations.

a. Vaccinations - Pharmacists in Queensland are now able to administer a limited range of vaccines and the Queensland Pharmacist Immunisation Pilot (QPIP) has demonstrated that they are able to do so safely, effectively and efficiently. It is proposed that the list of vaccines that pharmacists are allowed to administer is expanded to cover those vaccines commonly required in pre-travel consultations. Of course, if approved, pharmacists would complete the additional training requirements associated with those vaccines.

### I. Vaccines - Routine

Haemophilus influenza type b

Hepatitis B

Human papillomavirus (HPV)

Influenza

Measles, mumps, rubella

Meningococcal (quadrivalent)

Pneumococcal

Polio

Rotavirus (for young children)

Tetanus, diphtheria, pertussis

Varicella

Zoster

### II. Vaccines - Travel

Cholera (Dukoral®)

Hepatitis A

Japanese encephalitis

Rabies

Tickborne encephalitis

**Typhoid** 

Yellow fever

b. Antibiotics and antimalarials - Pharmacists in Queensland are currently unable to supply antibiotics and antimalarials without prescription. However, the upcoming *Pharmacist-led management of uncomplicated UTIs trial* will educate pharmacists on how to judiciously and appropriately supply antimicrobials following standardised management protocols and antimicrobial stewardship principles. Traveller's diarrhoea, respiratory and urinary tract infections and the supply of chemoprophylaxis for travellers visiting malaria-endemic areas are common travel health interventions.<sup>7-9,35-40</sup> Therefore, it is recommended that the range of antimicrobials used in the upcoming *Pharmacist-led management of* 

uncomplicated UTIs trial can be expanded to include the antimicrobials and antimalarial agents list in Appendix I. It would be recommended that a model of pharmacist prescribing that mimics the prescriptive authority model used in the province of Alberta, Canada or the Patient Group Directives used in the UK is adopted. These are autonomous prescribing models with pharmacists making prescribing decisions following best practice protocols and are similar to existing prescribing arrangements for Nurse Practitioners in Queensland.

The <u>Pharmacy Guild's submission</u> to the Pharmacy Board of Australia on pharmacist prescribing in April 2019 further outlines Autonomous Prescribing models in Australia as a way to address the public need for improving medicines access and management.

- c. Other medicines Appendix I also list a small number of agents that may be useful in specific situations such as the prevention of altitude illness, venous thromboembolism and jet lag. If approved for use by pharmacists, these would be prescribed by pharmacists for specific situations and in the same manner as described in subsection b above.
  - 3.1.3. Risk communication providing reliable, current and evidence-based, written and verbal, information

A series of pharmacy-specific educational resources were developed for the NQ PTC pilot and the range would be further expanded. Most pharmacists already possess good verbal interviewing and counselling skills however travel-specific interviewing and counselling skills are also covered in the training package developed for the NQ PTC pilot.

### 3.1.4. A formal and thorough assessment system for returning travellers to identify travelrelated health problems and ensure the appropriate treatment of any health problems

As in subsection 3.1.1, as part of the North Queensland PTC pilot, a comprehensive literature review was performed to identify all of the key components of a post-travel risk assessment and to develop a systematic and standardised questionnaire and interview tool to aid the interview process. These can also be adapted for electronic use via the GuildCare IT platform.

### 3.1.5. The care and advice given to the traveller is documented and recorded

The intention would be that occasions of service are documented in a format that may be uploaded to the traveller's My Health Record and shared with the traveller's nominated GP.

### 4. Summary

In conclusion, pharmacies are ideal sites from which travel health services can operate and community pharmacy-run travel health services may be attractive to certain niche groups of travellers. In particular, to travellers who may not use the services offered by other health providers. The inability to administer travel-specific vaccines and to supply a limited range of medications and antimalarials limits the services that can be offered from community pharmacies. Overseas experience shows that expanding the range of vaccinations and medicines available from pharmacies to include travel-specific vaccines, antimalarials and a limited range of antimicrobials and other medications will significantly improve the level of services available from pharmacies and thereby reduce the risks of travel for Australians.

I.M.Heslop October 2019 8

### 5. References

- World Tourism Organization (2018), UNWTO Annual Report 2017, UNWTO, Madrid, DOI: https://doi.org/10.18111/9789284419807
- Glaesser D, Kester J, Paulose H et al. Global travel patterns: an overview. Journal of Travel Medicine 2017: 24: 1–5.
- 3. Field VK, Ford L, Hill DR, editors. *Health Information for Overseas Travel*. London: National Travel Health Network and Centre, 2010.
- 4. Spira AM. Travel medicine I: Preparing the traveller. The Lancet 2003;361:1368-81.
- 5. Steffen R, deBernardis C, Banos A. Travel epidemiology a global perspective. International Journal of Antimicrobial Agents 2003;**21**:89-95.
- Rack J, Wichmann O, Kamara B, et al. Risk and spectrum of diseases in travelers to popular tourist destinations. Journal of Travel Medicine 2005;12(5):248-53.
- 7. Leggat P, Goldsmid J. Travellers' diarrhoea. In: Leggat PA, Goldsmid JM, eds. Primer of Travel Medicine. Revised 3rd ed. Brisbane: ACTM Publications, 2005:175-87.
- 8. Goodyer L. Travel medicine (2): Travellers' diarrhoea. The Pharmaceutical Journal 1999;**263**:571-75.
- Connor BA. Travelers' diarrhea. Chapter 2 Preparing international travelers. In: Brunette GW, ed. CDC Health Information for International Travel 2020. New York: Oxford University Press, 2017:114-121.
- 10. Batchelor T. SPUMS Annual scientific meeting 2002: Traveller's diarrhoea. South Pacific Underwater Medicine Society (SPUMS) Journal 2002;**32**(4):207-10.
- 11. Shaw M. Running a travel clinic. Travel Medicine and Infectious Disease 2006;4:109-26.
- 12. Seelan ST, Leggat PA. Referral of travellers from Australia by general practitioners for travel health advice. Travel Medicine and Infectious Disease 2003;1:185-88.
- 13. Van Herck K, Zuckerman J, Castelli F, et al. Traveler's knowledge, attitudes, and practices on prevention of infectious diseases: Results from a pilot study. Journal of Travel Medicine 2003;**10**(2):75-78.
- 14. Van Herck K, Castelli F, Zuckerman J, et al. Knowledge, attitudes and practices in travel-related infectious disease: The European airport survey. Journal of Travel Medicine 2004;**11**(1):3-8.
- 15. Wilder-Smith A, Khairullah NS, Song J-H, et al. Travel health knowledge, attitudes and practices among Australasian travelers. Journal of Travel Medicine 2004;**11**(1):9-15.
- 16. Toovey S, Jamieson A, Holloway M. Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: Results from a study at Johannesburg International Airport. Journal of Travel Medicine 2004;11(1):16-22.
- 17. Hamer DH, Connor BA. Travel health knowledge, attitudes and practices among United States travelers. Journal of Travel Medicine 2004;11(1):23-26.
- Namikawa K, Iida T, Ouchi K, et al. Knowledge, attitudes and practices of Japanese travelers on infectious disease risks and immunization uptake. Journal of Travel Medicine 2010;17(3):171-75
- 19. Kodkani N, Jenkins JM, Hatz CF. Travel advice given by pharmacists. Journal of Travel Medicine 1999;**6**(2):87-92.
- 20. Goad JA. Travel medicine and the role of the pharmacist. Advances in Pharmacy 2004;**2**(4):318-14.
- 21. Hind CA, Bond CM, Lee AJ, et al. Needs assessment study for community pharmacy travel medicine services. Journal of Travel Medicine 2008;**15**(5):328-34.
- 22. Heslop IM, Speare R, Bellingan M et al. Australian pharmacists' perceptions and practices in travel health. Pharmacy 2018; **6**, 90; doi:10.3390/pharmacy6030090
- 23. Mason P. What advice can pharmacists offer travellers to reduce their health risks? The Pharmaceutical Journal 2004;**273**:651-56.
- 24. Goodyer L. Travel medicine (1): Role of the pharmacist and sources of information. The Pharmaceutical Journal 1999;**263**:84-87.
- 25. Jackson AB, Humphries TL, Nelson KM, et al. Clinical pharmacy travel medicine services: A new frontier. The Annals of Pharmacotherapy 2004;**38**:2160-65.
- 26. Brennan C. Pharmacist-run travel medicine clinic. The Annals of Pharmacotherapy 2004;**38**:2168-69.
- 27. Hind C, Bond C, Lee AJ, et al. Travel medicine services from community pharmacy: Evaluation of a pilot service. The Pharmaceutical Journal 2008;**281**:625-28.
- 28. Hind C, Downie G. Vaccine administration in pharmacies A Scottish success story. The Pharmaceutical Journal 2006;**277**:134-36.

- 29. Gatewood SBS, Stanley DD, Goode J-VR. Implementation of a comprehensive pretravel health program in a supermarket chain pharmacy. Journal of the American Pharmacists Association 2009;**49**(5):660-69.
- 30. Hess KM, Dai C-W, Garner B, et al. Measuring outcomes of a pharmacist-run travel health clinic located in an independent community pharmacy. Journal of the American Pharmacists Association 2010;50(2):174-80.
- 31. Connelly D. A pharmacist-led travel health clinic. The Pharmaceutical Journal 2007;279:47.
- 32. Durham MJ, Goad JA, Neinstein LS, et al. A comparison of pharmacist travel-health specialists' versus primary care providers' recommendations for travel-related medications, vaccinations, and patient compliance in a college health setting. Journal of Travel Medicine 2011;**18**(1):20-25.
- 33. Goode J-VR, Mott DA, Stanley DD. Assessment of an immunization program in a supermarket chain pharmacy. Journal of the American Pharmacists Association 2007;47(4):495-98.
- 34. Seed SM, Spooner LM, O'Connor K, et al. A multidisciplinary approach in travel medicine. Journal of Travel Medicine 2011;**18**(5):352-54.
- 35. Leggat PA, Ross MH, Goldsmid JM. Introduction to travel medicine. In: Leggat PA, Goldsmid JM, eds. Primer of Travel Medicine. Revised 3rd ed. Brisbane: ACTM Publications, 2005:3-21.
- 36. Leggat PA. Risk assessment in travel medicine. Travel Medicine and Infectious Disease 2006;**4**:127-34.
- 37. 116. Gherardin T. The pre-travel consultation: An overview. Australian Family Physician 2007;**36**(5):300-03.
- 38. Stringer C, Chiodini J, Zuckerman J. International travel and health assessment. Nursing Standard 2002;**16**(39):49-54.
- 39. Chen LH, Hochberg NS. The pre-travel consultation. Chapter 2 Preparing international travelers. In: Brunette GW, ed. CDC Health Information for International Travel 2020. New York: Oxford University Press, 2017:9-17.
- Tan KR, Arguin PM. Malaria. Chapter 4 Travel-related infectious diseases. In: Brunette GW, ed. CDC Health Information for International Travel 2020. New York: Oxford University Press, 2017:267-287.

### 6. Appendices

Appendix I: Suggested Schedule 4 Prescription Only Medicines and Vaccines required for routine pre-travel consultations

### 1. Antibiotics and Antimalarials

### a) Antibiotics - for Travellers' diarrhoea

Azithromycin, Ciprofloxacin, Norfloxacin

### b) Antibiotics - for urinary tract infections

Trimethoprim, Cephalexin, Nitrofurantoin, Amoxicillin/clavulanic acid

### c) Antimalarials for chemoprophylaxis

Atovaquone with proguanil, Doxycycline, Mefloquine

### d) Antimalarials for stand-by treatment

Artemether with lumefantrine

### 2. Vaccines to update or consider during pre-travel consultations

### a) Vaccines - Routine

Haemophilus influenza type b

Hepatitis B

Human papillomavirus (HPV)

Influenza

Measles, mumps, rubella

Meningococcal (quadrivalent)

Pneumococcal

Polio

Rotavirus (for young children)

Tetanus, diphtheria, pertussis

Varicella

Zoster

### b) Vaccines - Travel

Cholera (Dukoral®)

Hepatitis A

Japanese encephalitis

Rabies

Tickborne encephalitis

Typhoid

Yellow fever\*

### c) Other agents\*

### i. Altitude Illness\*

Acetazolamide

Dexamethasone

Nifedipine

### ii. VTE Prophylaxis\*

Enoxaparin

### iii. Jet Lag\*

Melatonin (compounded preparation)

\*Optional depending on the level of pre-travel consultation offered